Guide for Commenting on ICER’s Draft Evidence Report on Treatments for Hypertrophic Cardiomyopathy

On August 18, 2021, ICER released its draft evidence report, “Mavacamten for Hypertrophic Cardiomyopathy: Effectiveness and Value.” This guide provides a framework for considering what aspects of the new hypertrophic cardiomyopathy treatment are important to patients and their families, and how to consider presenting those perspectives. This guide specifically provides insights about how to read and respond to ICER’s “draft evidence report,” as well as how to request a slot to make comments during ICER’s public meeting.  

View/Download the Guide (PDF)